Timing Between Rizatriptan and Zolmitriptan Administration
You must wait at least 24 hours after taking rizatriptan 10 mg before administering zolmitriptan nasal spray. This is an absolute contraindication based on FDA labeling and applies to all triptan-to-triptan transitions. 1
Critical Safety Requirement
The FDA explicitly contraindicates the use of any 5-HT1 agonist (including zolmitriptan) within 24 hours of another 5-HT1 agonist (such as rizatriptan). 1 This restriction exists to prevent:
- Additive vasospastic effects that can lead to serious cardiovascular events including myocardial infarction, stroke, and peripheral vascular ischemia 1, 2
- Cumulative serotonergic toxicity that may precipitate serotonin syndrome 2
- Excessive vasoconstriction affecting coronary, cerebral, and peripheral vessels 1, 2
Practical Clinical Algorithm
If a patient takes rizatriptan 10 mg and the migraine persists or recurs:
Within the first 2 hours: The patient may take a second dose of rizatriptan (up to 30 mg total in 24 hours, typically given as three 10 mg doses at 2-hour intervals) 3
Between 2-24 hours: The patient should use non-triptan rescue medications such as NSAIDs or acetaminophen, but cannot use zolmitriptan or any other triptan 1
After 24 hours have elapsed: Zolmitriptan nasal spray may be safely administered for a new attack 1
Important Caveats
Same-triptan dosing is permitted: A patient can take additional doses of the same triptan (rizatriptan in this case) at appropriate intervals within the 24-hour period, respecting maximum daily limits 3, 1
Maximum daily limits matter: Rizatriptan has a 30 mg/24-hour maximum 3, while zolmitriptan has a 10 mg/24-hour maximum 1. These limits apply independently but cannot overlap within the same 24-hour window 1
The 24-hour rule is bidirectional: If a patient takes zolmitriptan first, they must also wait 24 hours before taking rizatriptan 1
This applies to all formulations: The restriction applies regardless of whether zolmitriptan is given as nasal spray, oral tablet, or orally disintegrating tablet 1
Clinical Rationale
The combination therapy evidence from recent guidelines supports triptan use with NSAIDs or acetaminophen for enhanced efficacy 4, but never supports combining two different triptans. The vasoconstrictive mechanisms of all triptans are similar enough that concurrent use creates unacceptable cardiovascular risk 1, 2.